Clera home
·Dashboard

Jobs at Aktis Oncology (Now Hiring) — 2 open

Aktis Oncology logoAktis Oncology

Scientist (all levels) – Radiopharmaceutical

Boston, Massachusetts, United States · On-site

$108k–$167k/yr

Mid level$331M raised

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform …

Skills: Radiolabeling, Metal chelation chemistry, Analytical method development, Radio-HPLC, Gamma detectors

Aktis Oncology logoAktis Oncology

Manager, Clinical Supply Chain

Boston, Massachusetts, United States · On-site

$123k–$150k/yr

Senior$331M raised

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform …

Skills: Clinical Supply Chain Management, Inventory Management, Logistics Operations, Data Analysis, Advanced Excel

Aktis Oncology logo

Scientist (all levels) – Radiopharmaceutical

Aktis Oncology

Boston, Massachusetts, United States • On-site

Apply
Mid level

Tired of cold applications?

Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.

  • $108k–$167k/yr
  • Full-time
  • bachelor degree
  • Posted 23h ago
  • ~40 hrs/week

Responsibilities

The scientist will support manufacturing and QC development of radiopharmaceutical drug products, including radiolabeling and formulation optimization. They will also manage laboratory operations, ensure regulatory compliance, and write development reports for technology transfer.

Requirements

Candidates must hold at least a bachelor's degree in chemistry, engineering, or a related field with relevant industry experience. Hands-on experience with metal chelation chemistry, radiolabeling, and analytical techniques like HPLC is required.

Full job description

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

DESCRIPTION

Aktis Oncology is seeking highly motivated scientists to support manufacturing and QC development of AKTIS Oncology’s proprietary radiopharmaceutical drug products. The candidate will be part of radiolabeling development, formulation optimization, and establishment of initial analytical methods within the RPD group. These roles are critical in ensuring product quality, regulatory compliance, and successful advancement of radiopharmaceutical programs from early development through clinical manufacturing. The position(s) will collaborate closely with cross-functional team members to ensure timely delivery of robust manufacturing protocols in support of technology transfer activities.  The ideal candidate has hands-on experience in radiolabeling and handling radioactive materials and radiopharmaceutical analytical techniques. This role requires full-time on-site presence at the Aktis Boston office.

RESPONSIBILITIES

This role will drive several areas of strategic importance to Aktis:

  • Radiolabeling and analytical method development of Aktis’ radioactive drug products for pre-clinical and early phase clinical use.
  • Participate in day-to-day laboratory operations, including radiation safety.
  • Write development reports that can be used for transfer of technology and regulatory filing.
  • Take on new challenges willingly and build a culture of rigor and data-driven decision making to bring novel therapies to the clinic
  • Demonstrate high standards for scientific rigor, team behaviors, excellence and a culture of innovation that is fully aligned with company objectives
  • Operate and maintain radio-HPLC systems, detectors, and analytical instruments

QUALIFICATIONS

  • Minimum BS in chemistry, engineering or related field, with relevant industry experience
  • Hands-on experience with metal chelation chemistry, radiolabeling methods and handling radioactive materials. 
  • Experience analyzing radiolabeled compounds, experience with gamma detectors, UV- and radio-HPLC
  • Experience with protein solubility, binding assays, and drug product formulation
  • Experience with HPLC troubleshooting and maintenance
  • Project management and organizational skills, proven track record of setting priorities, and ability to work independently and as a team member.
  • Strong desire to be part of a mission‐oriented company leading transformative change for patients.
  • Proven demonstration of transparent communication and fostering open and diverse debate.
  • Ability to work with agility and manage ambiguity.
  • Personifies positive energy and exemplifies respect.

Aktis Oncology is an Equal Opportunity Employer and does not discriminate on the basis of race, religion, color, sex, gender identity or expression, sexual orientation, age, disability, national origin, veteran status, or any other basis covered by appropriate law. Aktis Oncology is committed to promoting and maintaining a work environment in which all applicants, employees, and other individuals are treated with dignity and respect free from unlawful harassment, discrimination, or retaliation.

Related keywords

RadiopharmaceuticalOncologyMiniproteinRadioconjugateManufacturingQC developmentRadiolabelingFormulation optimizationAnalytical methodsRPD groupRegulatory complianceTechnology transferMetal chelation chemistryRadio-HPLCGamma detectorsUV-HPLC

About Aktis Oncology

LinkedInVisit site

Expanding the breakthrough potential of targeted radiopharmaceuticals to large cancer patient populations.

Industry
Biotechnology Research
Company size
51-200 employees
LinkedIn followers
12,981
Total funding
$331M

Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.

Health CareOncologyBiotechnologyLife Science
View all jobs at Aktis Oncology

About Aktis Oncology

LinkedInVisit site

Expanding the breakthrough potential of targeted radiopharmaceuticals to large cancer patient populations.

Industry
Biotechnology Research
Company size
51-200 employees
LinkedIn followers
12,981
Total funding
$331M

Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Aktis’ most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. The company also maintains a strategic collaboration with Eli Lilly and Company to develop novel anticancer radiopharmaceuticals for targets outside of Aktis’ proprietary pipeline.

Health CareOncologyBiotechnologyLife Science
View all jobs at Aktis Oncology

Similar companies hiring

Thermo Fisher Scientific (2423)Roche (1209)CSL (1046)Amgen (885)ICON plc (787)Syneos Health (399)Mineralys Therapeutics, Inc. (315)Agilent Technologies (282)Fortrea (270)Gilead Sciences (231)BeiGene (193)Genentech (184)
Clera home

Your AI-talent agent. Connecting talents with dream jobs.

Earn $5,000

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Case Studies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Case Studies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

© 2026 Clera Labs, Inc.

PrivacyTermsBug Bounty